CYP cynata therapeutics limited

Cynata’s lowly valuation leads investors to ponder the ‘sliding...

  1. 16,287 Posts.
    lightbulb Created with Sketch. 6187
    Cynata’s lowly valuation leads investors to ponder the ‘sliding doors’ moment of Sumitomo’s 2019 provisional $2 a share cash bid for the company, which didn’t get over the line. But Dr Kelly is unfazed.


    No dramas @Pledge .... it's all good ... Dr Kelly is unfazed about Sumitomo $2 offer falling over.... I can see his point and I am sure many CYP LT holders are unfazed as well... I mean what's $1.85 per share between friends 4 years down the track ?


    There are certainly a number of bold statements in the article ... some I think are a little over the top but hey he is now in control of CYP so he is putting it all out there on record in the public arena so he must be a little confident (or perhaps arrogant) ? let's see how it all unfolds in the coming 12-18 months
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.0¢
Change
0.000(0.00%)
Mkt cap ! $36.15M
Open High Low Value Volume
16.0¢ 16.0¢ 16.0¢ $1.021K 6.379K

Buyers (Bids)

No. Vol. Price($)
4 77738 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.5¢ 3400 1
View Market Depth
Last trade - 09.59am 24/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.